Hospital Group Mum As Members Pursue Patients With Lawsuits And Debt Collectors
The influential trade association has said little over the years as health systems, including those of its own trustees, seized patients’ incomes and assets. Now it is reevaluating.
UVA Doctors Decry Aggressive Billing Practices By Their Own Hospital
In the wake of a Kaiser Health News investigation, doctors want the University of Virginia’s health system to stop suing its patients over unpaid bills.
As UVA Scales Back Lawsuits, Pain For Past Patients Persists
Patients were thrilled last month when UVA announced it would scale back lawsuits and provide more financial assistance, but the excitement has waned.
VCU Health Will Halt Patient Lawsuits, Boost Aid In Wake Of KHN Investigation
Patients at VCU Health will no longer be taken to court and can more easily get financial assistance to pay their bills.
UVA To Cut Back On Lawsuits Against Patients
But critics say the new policy still leaves some patients exposed to lawsuits and crippling bills.
UVA Suspends Medical Lawsuits In Wake Of KHN Investigation
KHN reported this week that the University of Virginia Health System has filed 36,000 lawsuits against patients the past six years.
Virginia Governor And UVA Vow To Revamp Practice Of Suing Patients As CEO Exits
A Kaiser Health News investigation, which first appeared in The Washington Post, showed that the University of Virginia Health System has sued patients 36,000 times for more than $106 million.
‘UVA Has Ruined Us’: Health System Sues Thousands Of Patients, Seizing Paychecks And Claiming Homes
Over six years, the state institution filed 36,000 lawsuits against patients seeking a total of more than $106 million in unpaid bills, a KHN analysis finds.
Pharma Cash Rolls Into Congress To Defend An Embattled Industry
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as “authorized generics,” in-house spinoffs of brand-name drugs quietly undermine the competition.
Americans Ready To Crack Down On Drug Prices That Force Some To Skip Doses
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
Pharma Execs Dig In For A Fight Against Outraged Senators
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Congress Squares Off With Pharma CEOs In Showdown Over High Drug Prices
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
Talk About Déjà Vu: Senators Set To Re-Enact Drug Price Hearing Of 60 Years Ago
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
False Lead: Senator’s Offer To Help Patient Import Cheap Insulin Goes Nowhere
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
Trump Administration Salutes Parade Of Generic Drug Approvals, But Hundreds Aren’t For Sale
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
Winners And Losers Under Bold Trump Plan To Slash Drug Rebate Deals
The White House and HHS want to eliminate a “shadowy system of kickbacks” in the drug industry pipeline.
Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Chronically Ill, Traumatically Billed: The $123,000 Medicine For MS
Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
High-Deductible Health Plans Fall From Grace In Employer-Based Coverage
Once viewed as a promising cost-control tool, such insurance faces new competition on benefits menus from more traditional insurance. But, according to new research, none of those choices is getting less expensive.
